fluorouracil has been researched along with Epstein-Barr Virus Infections in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "As EBV-associated gastric cancer has unique features that are different from EBV (-) gastric cancer, EBV is considered to have a key role in gastric carcinogenesis." | 1.36 | LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. ( Chae, HS; Kang, JH; Kim, JO; Lee, SK; Shin, JY, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, SL | 1 |
| Sun, XS | 1 |
| Xie, HJ | 1 |
| Chen, QY | 1 |
| Lin, HX | 1 |
| Liang, H | 1 |
| Liang, YJ | 1 |
| Li, XY | 1 |
| Yan, JJ | 1 |
| Lin, C | 1 |
| Yang, ZC | 1 |
| Guo, SS | 1 |
| Liu, LT | 1 |
| Tang, QN | 1 |
| Du, YY | 1 |
| Tang, LQ | 1 |
| Guo, L | 1 |
| Mai, HQ | 1 |
| Lo, AK | 1 |
| Lo, KW | 1 |
| Ko, CW | 1 |
| Young, LS | 1 |
| Dawson, CW | 1 |
| Yanai, H | 1 |
| Yahara, N | 1 |
| Furuya, T | 1 |
| Hayashi, H | 1 |
| Murakami, T | 1 |
| Shimokawa, Y | 1 |
| Sugihara, S | 1 |
| Chua, ML | 1 |
| Tan, SH | 1 |
| Kusumawidjaja, G | 1 |
| Shwe, MT | 1 |
| Cheah, SL | 1 |
| Fong, KW | 1 |
| Soong, YL | 1 |
| Wee, JT | 1 |
| Tan, TW | 1 |
| Shin, JY | 1 |
| Kim, JO | 1 |
| Lee, SK | 2 |
| Chae, HS | 1 |
| Kang, JH | 1 |
| Bossi, P | 1 |
| Orlandi, E | 1 |
| Bergamini, C | 1 |
| Locati, LD | 1 |
| Granata, R | 1 |
| Mirabile, A | 1 |
| Parolini, D | 1 |
| Franceschini, M | 1 |
| Fallai, C | 1 |
| Olmi, P | 1 |
| Quattrone, P | 1 |
| Potepan, P | 1 |
| Gloghini, A | 1 |
| Miceli, R | 1 |
| Mattana, F | 1 |
| Scaramellini, G | 1 |
| Licitra, L | 1 |
| Seo, JS | 1 |
| Kim, TG | 1 |
| Hong, YS | 1 |
| Chen, JY | 1 |
| Rodriguez-Galindo, C | 1 |
| Wofford, M | 1 |
| Castleberry, RP | 1 |
| Swanson, GP | 1 |
| London, WB | 1 |
| Fontanesi, J | 1 |
| Pappo, AS | 1 |
| Douglass, EC | 1 |
| Lin, JC | 1 |
| Chen, KY | 1 |
| Wang, WY | 1 |
| Jan, JS | 1 |
| Liang, WM | 1 |
| Tsai, CS | 1 |
| Wei, YH | 1 |
| Feng, WH | 1 |
| Israel, B | 1 |
| Raab-Traub, N | 1 |
| Busson, P | 1 |
| Kenney, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma[NCT04456322] | Phase 3 | 326 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Randomized Phase II Trial of Concurrent Chemoradiotherapy With or Without Nimotuzumab for High Risk Nasopharyngeal Carcinoma After Induction Chemotherapy[NCT04223024] | Phase 2 | 246 participants (Actual) | Interventional | 2019-12-12 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fluorouracil and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla | 2005 |
9 other studies available for fluorouracil and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Disease-F | 2020 |
Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Car | 2013 |
Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deox | 2016 |
LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cell | 2010 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2011 |
Contribution of Epstein-Barr virus infection to chemoresistance of gastric carcinoma cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Culture Techniques; Cell Line, T | 2011 |
Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Combin | 2001 |
Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carcinoma; Cisplatin; Dru | 2002 |